Amyloid beta (Aβ)

Where the papers sit

40 papers from the last 6 months study Amyloid beta (Aβ) directly · updated from PubMed 12 Oct 2026

• Aβ Aggregation and Toxicity

  Aβ research is targeting the transition from soluble peptide to toxic aggregates, while also addressing the downstream synaptic and inflammatory damage. Metal chelation, GLP-1 receptor agonism, lysosomal restoration and NF-κB suppression represent complementary intervention routes. Nanoparticles and phytochemical-derived hybrids combine aggregation, cholinesterase or neuroinflammation targets. Computational structure and peptide-aggregation models are increasingly being used to prioritize compounds, but broad efficacy remains unestablished.

  11 papers · 27.5%

• Anti-Aβ Immunotherapy and Biomarkers

  Anti-Aβ treatment is shifting toward direct comparison of antibody binding, pathological effects and treatment response. Aducanumab, lecanemab and ACU193 studies examine how target engagement relates to amyloid, tau and downstream brain changes. CSF and plasma biomarker panels are being used to map ATN transitions and distinguish responders from non-responders. Nanoparticle–antibody conjugates aim to improve delivery by limiting hepatic sequestration, while neuroinflammation and synaptic injury remain additional therapeutic targets.

  10 papers · 25%

• Tau Biomarkers and Cognition

  Tau biomarkers are being linked more closely to cognitive decline and disease stage across the Alzheimer disease spectrum. Plasma tau signatures, tau PET, cerebrospinal measures and combined biomarker trajectories support earlier stratification. Cerebral blood flow and white matter lesions are being evaluated as modifiers of amyloid–tau relationships. Assay validation, longitudinal modeling and personalized data use remain central unresolved needs.

  9 papers · 22.5%

• Blood-Brain Barrier Aβ Therapies

  Aβ research is moving toward agents that cross the blood–brain barrier while blocking aggregation or enabling diagnosis. Natural inhibitors, xanthene compounds and ApoE3-targeted liposomes are being paired with multimodal delivery strategies. Butyrate studies emphasize how barrier transport and endothelial accumulation shape exposure. PET, near-infrared and smartphone fluorescence approaches extend this work into detection and theranostics.

  6 papers · 15%

• Early Alzheimer Disease Assessment

  Early Alzheimer disease assessment is converging on clinical outcomes, plasma biomarkers and standardized amyloid measurement. Donanemab data connect amyloid removal with meaningful benefit in early symptomatic disease, while head-to-head assay studies address cross-platform comparability. Metabolite signatures and plasma P-tau181 may refine detection before dementia develops. Their predictive value still requires validation across cohorts and against long-term cognitive outcomes.

  4 papers · 10%